Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
|Mar 15, 2017||CT ORDER||confidential treatment order|
|Mar 2, 2017||S-8||registration statement|
|Mar 2, 2017||10-K||annual report|
|Mar 2, 2017||8-K||current report|
|Feb 14, 2017||SC 13G/A||amended statement of beneficial ownership|
The Chimerix ticker is CMRX and it is traded on the Nasdaq Global Market.
2505 Meridian Parkway
Durham, NC 27713
You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.
You can view our management team by visiting the Management section of our Investor Relations website.
Chimerix does not expect to declare or pay any cash or other dividends on our common stock.
Chimerix does not currently have a direct stock purchase plan.
The transfer agent and registrar for our common stock is:
Computershare Trust Company, N.A.
The transfer agent and registrar’s address is:
P.O. Box 43078
Providence, Rhode Island 02940
Please submit your question using the form below.